Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSME2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSME2 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. |
View PSME2 Products |
| Gene Delivery | PSME2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View PSME2 Products |
| Benchmark Ab | Anti-PSME2 Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and IHC. |
View PSME2 Products |
| Validator | PSME2 siRNA Set Target-specific gene knockdown verification in cell-based functional assays. |
View PSME2 Products |
| Related Target A | PSME1 Essential partner that obligatorily co-assembles with PSME2 to form the active PA28alpha/beta proteasome regulator. |
View PSME1 Products |
| Related Target B | PSME3 Homologous proteasome activator (PA28gamma) involved in nuclear proteasomal degradation and cell cycle regulation. |
View PSME3 Products |
| Related Target C | PSMB8 Immunoproteasome subunit catalytic core (LMP7) that functionally cooperates with the PA28 complex. |
View PSMB8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting active PA28alpha/beta hetero-oligomer complex | Highly purified, sequence-verified PSME1 and PSME2 proteins available for precise stoichiometry mixing. |
| Selectivity screening against homologous proteasome activators | Homolog panel including PSME3 and PSME4 proteins strictly validated by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included |
| False Positives in phenotypic assays | Validated sequence-specific siRNA pool included for target-specific knockdown verification |
Live PSME2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the proteasome system is undergoing a paradigm shift. While traditional proteasome inhibitors (like bortezomib) broadly target the 20S catalytic core, emerging drug discovery programs are focusing on regulatory subunits to achieve tissue-specific and pathway-specific modulation. PSME2 (PA28beta), as an essential component of the 11S (PA28) regulator, is a prime target in this new wave of R&D.
The race for PSME2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule protein-protein interaction (PPI) inhibitors and RNA-targeting modalities. As first-generation immunoproteasome therapies reach the clinic, the next wave of R&D is targeting the precise disruption of the PSME1/PSME2 hetero-heptamer to modulate antigen presentation in autoimmune diseases and oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / PPI Inhibitors | Biotech / Academic Consortia | Autoimmune Diseases, Chronic Inflammation | In vitro reconstitution assay (Requires high-purity, low-endotoxin PSME1 and PSME2 proteins) |
| siRNA / Oligonucleotides | RNAi Therapeutics Developers | Inflammatory Disorders, Cancer Immunotherapy | Target knockdown validation (Requires sequence-verified PSME2 siRNA and Lentivirus for stable lines) |
| Monoclonal Antibodies (Research/Diagnostic) | Diagnostic & Reagent Developers | Biomarker Profiling in Solid Tumors | Epitope mapping and specificity screening (Requires sequence-verified antigen panels) |